TW200512293A - Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics - Google Patents

Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Info

Publication number
TW200512293A
TW200512293A TW093116334A TW93116334A TW200512293A TW 200512293 A TW200512293 A TW 200512293A TW 093116334 A TW093116334 A TW 093116334A TW 93116334 A TW93116334 A TW 93116334A TW 200512293 A TW200512293 A TW 200512293A
Authority
TW
Taiwan
Prior art keywords
eif
apoptosis
sirnas
specific
inhibition
Prior art date
Application number
TW093116334A
Other languages
English (en)
Chinese (zh)
Inventor
John E Thompson
Catherine Taylor
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of TW200512293A publication Critical patent/TW200512293A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW093116334A 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics TW200512293A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47619403P 2003-06-06 2003-06-06
US50473103P 2003-09-22 2003-09-22
US52824903P 2003-12-10 2003-12-10
US55767104P 2004-03-31 2004-03-31
US57581404P 2004-06-02 2004-06-02

Publications (1)

Publication Number Publication Date
TW200512293A true TW200512293A (en) 2005-04-01

Family

ID=34084831

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116334A TW200512293A (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Country Status (9)

Country Link
EP (1) EP1636364A2 (fr)
JP (1) JP5666074B2 (fr)
KR (1) KR20060013428A (fr)
AU (1) AU2004258070B2 (fr)
CA (1) CA2528372A1 (fr)
IL (1) IL172365A0 (fr)
NZ (2) NZ544159A (fr)
TW (1) TW200512293A (fr)
WO (1) WO2005007853A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
EP1601767B1 (fr) 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
EP1769075A2 (fr) * 2004-07-20 2007-04-04 Senesco Technologies, Inc. Utilisation d'arnsi eif-5a specifiques de l'apoptose et de polynucleotides antisens pour inhiber/supprimer une reponse inflammatoire
NZ556236A (en) * 2004-12-03 2009-12-24 Senesco Technologies Inc Apoptosis-specific eIF-5A and polynucleotides encoding same
WO2007070824A2 (fr) * 2005-12-13 2007-06-21 Senesco Technologies, Inc. Utilisation d'eif-5a pour detruire les cellules d'un myelome multiple
EP1996707A2 (fr) * 2006-03-20 2008-12-03 Senesco Technologies, Inc. Nouvelle méthode pour la protection d'îlots de langerhans de l'apoptose au cours du processus de prélèvement chez un donneur
KR20080082688A (ko) * 2006-03-20 2008-09-11 세네스코 테크놀로지스 인코포레이티드 공여자의 섬 세포 채취 과정 동안에 섬 세포를아폽토시스로부터 보호하는 신규 방법
KR20080070879A (ko) * 2006-03-20 2008-07-31 세네스코 테크놀로지스 인코포레이티드 패혈증 또는 출혈성 쇼크를 치료하기 위한 ｅＩＦ-5Ａ1ｓｉＲＮＡ 및 안티센스의 용도
WO2007115047A2 (fr) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. INHIBITION DE LA RÉPLICATION DU VIH ET DE L'EXPRESSION DE p24 PAR LE BIAIS D'elF-5
US20090093434A1 (en) * 2007-08-20 2009-04-09 Senesco Technologies, Inc. Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality
CN102282259A (zh) 2008-03-07 2011-12-14 森尼斯科技术公司 与有义构建体实现期望多核苷酸的表达的用途相组合的、sirna实现内源基因的减量调节的用途
WO2009144933A1 (fr) * 2008-05-27 2009-12-03 国立大学法人東京大学 Inducteur de l'apoptose
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173897A (zh) * 1995-02-13 1998-02-18 诺瓦蒂斯有限公司 真核起始因子5A(eIF－5A)突变体
CA2448320A1 (fr) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7381708B2 (en) * 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
DK2280070T3 (en) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
EP1601767B1 (fr) * 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome

Also Published As

Publication number Publication date
JP2006526989A (ja) 2006-11-30
AU2004258070A1 (en) 2005-01-27
JP5666074B2 (ja) 2015-02-12
IL172365A0 (en) 2006-04-10
AU2004258070B2 (en) 2008-12-11
NZ574973A (en) 2010-10-29
CA2528372A1 (fr) 2005-01-27
WO2005007853A2 (fr) 2005-01-27
NZ544159A (en) 2009-04-30
EP1636364A2 (fr) 2006-03-22
KR20060013428A (ko) 2006-02-09
WO2005007853A3 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2004078940A3 (fr) Utilisation d'oligonucleotides antisens de siarn pour supprimer l'expression de eif-5a1
TW200512293A (en) Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
GB9927444D0 (en) Inhibiting gene expression
WO2003012052A3 (fr) Inhibition specifique d'expression de gene par de petits arns double brin
WO2007005645A3 (fr) Materiaux et procedes pour la generation de transcriptions d'acide nucleiques modifiee en 2'
WO2005118824A3 (fr) Methodes et compositions inhibant l'expression genique
WO2006119266A3 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
EP1537227A4 (fr) Procede d'interference efficace par arn dans des cellules de mammifere
WO2008078180A3 (fr) Matériaux et procédés pour la génération de transcrits comprenant des nucléotides modifiés
EP1490489A4 (fr) Methodes et moyens de surveillance et de modulation du blocage d'un gene
WO2006047842A3 (fr) Nucleosides modifies pour interference arn
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
EP1509251A4 (fr) Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose
WO2013040393A3 (fr) Gènes contribuant à la survie de cellules cancéreuses
TW200615001A (en) Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
NO960965L (no) Genet Grb3-3 med varianter derav samt deres anvendelse
WO2004016215A3 (fr) Utilisation d'oligonucleotides antisens pour inhiber l'expression de akt-1
WO2003106625A3 (fr) Ribozymes a tete de marteau
WO2007109674A3 (fr) Utilisation d'arnsi eif-5a spécifique de l'apoptose pour la régulation négative de l'expression de cytokines pro-inflammatoires afin de traiter la septicémie
ATE555201T1 (de) Verwendung von sirna zur abschaffung der expression von eif-5a1 in der behandlung von glaukoma
MD3300G2 (ro) Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
IL156171A0 (en) Dna encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5a, transgenic plants and a method for controlling senescence programmed and cell death in plants
AU3956100A (en) Rna polymerase i transcription factor tif-ia